Address
MPM Capital
601 Gateway Boulevard
Suite 350
South San Francisco, CA 94080
United States
Phone
Email
Website
Recent investment activity
KANDO id: 30789
Relation
Renamed to
Funding rounds
Top investment portfolio themes
nanotechnology (1)
Investment activity status
Active investor
Selected investments
Displaying 51 - 71 of 71Company | Profile | Country | Date | Funding | ||
---|---|---|---|---|---|---|
Acorda Therapeutics Inc | A biotechnology company whose mission is to develop and market therapeutic products for spinal cord injury and other central nervous system disorders. | N/A | ||||
Adolor Corp | N/A | |||||
Alnara Pharmaceuticals Inc | N/A | |||||
ARYx Therapeutics Inc | N/A Initial investment | |||||
AVEO Pharmaceuticals Inc | Biopharmaceutical company discovering, developing and commercializing cancer therapeutics. | N/A Initial investment | ||||
BioMarin Pharmaceutical Inc | N/A | |||||
Elixir Pharmaceuticals Inc | Series C Initial investment | |||||
EndoGastric Solutions Inc | Series E | |||||
EndoGastric Solutions Inc | Venture | |||||
EndoGastric Solutions Inc | Series B | |||||
EndoGastric Solutions Inc | Series A | |||||
Epizyme Inc | Focusing on the discovery and development of innovative drugs targeting epigenetic enzymes, in particular histone methyltransferases (HMTs). | Series B | ||||
Keryx Biopharmaceuticals Inc | N/A | |||||
MacroGenics Inc | Biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases. | Series C | ||||
Nanosys Inc | Nanotechnology-enabled systems | N/A | ||||
NeoVista Inc | Series E Follow-on investment | |||||
NeoVista Inc | Series D Follow-on investment | |||||
NeoVista Inc | Series C Initial investment | |||||
Portola Pharmaceuticals Inc | N/A | |||||
Rinat Neuroscience Corp | Discovers and commercializes novel antibody based drugs and drug targets for the major mental and neuro-degenerative diseases | Series B Initial investment |
Company | Profile | Funding | ||
---|---|---|---|---|
CODA Biotherapeutics | N/A Initial investment Exited Write-off |